Parexel has established The Expert Office, which provides a single point of contact for clients to more quickly access the company’s worldwide clinical research expertise.
The Expert Office aligns the company's leading medical, therapeutic area, regulatory, and clinical operations experts with their counterparts at biopharmaceutical companies. It is designed to deliver a new level of strategic partnering based on program design expertise, operational excellence, and project leadership.
"Biopharmaceutical companies face myriad regulatory, medical, and scientific issues that are changing the clinical development environment, and Parexel is committed to easing these challenges for our customers. The Expert Office has been designed to provide customers with access to a global team of experts who work closely with them to develop customized strategies and oversee the optimal execution of trials. The Expert Office signals a truly new level of strategic partnering between Parexel and our customers,” said Mark A. Goldberg, M.D., chief operating officer, Parexel.
The Expert Office includes top specialists in their fields, many of whom are former regulators, pharmaceutical company executives, and leaders of medical institutes. The team’s expertise spans phase I through phase IV clinical research and a broad range of therapeutic areas, including but not limited to oncology, cardiology, neurology, rheumatology, and infectious disease.
“Customers are increasingly looking to Parexel to provide insightful strategic guidance related to their compounds in development,” said Udo Kiessling, M.D., corporate vice president and chief medical officer, who heads The Expert Office at Parexel. “Our thought leaders form a comprehensive, cohesive team that provides a strong relationship among medical practice, regulatory affairs, and clinical operations across a broad range of therapeutic areas. This consolidation of knowledge throughout the lifecycle of a program is focused on helping biopharmaceutical companies make faster, better informed development and commercialization decisions and accelerate clinical research.”
